From Alchemy to IPO: The Business of Biotechnology
Author: Cynthia Robbins-Roth
List Price: $17.50
Our Price: Click to see the latest and low price
ISBN: 073820482X
Publisher: HarperCollins (10 April, 2001)
Sales Rank: 4,828
Average Customer Rating: 4.2 out of 5
Customer Reviews
Rating: 5 out of 5
Top of the line
This book is worth every dime and much more. Presents the latest twists and turns in biotech, including the early bonanza. Although every word is worth its place this is not heavy and booring at any time. Biotech is a field hard for 'outsiders' to grasp. After reading this book even a novice will feel at home and for the more wised it is just informative and above all also entertaining - qualities rarely found inside the same cover.
Rating: 2 out of 5
WAY OVERRATED BOOK ON BIOTECH
to quote another user: "The author's expertise in science, finance, management strategy, and journalism..." the author can write decently and she may know about biotech (hard to judge for me not being a scientist)...BUT her knowledge about management strategy and finance is limited at best...that wouldn't be so bad if she were to stick to write about science...however, she thinks she knows about finance and strategy...who wants to read about strategy should stick with hamel, pralahad, porter etc., who wants to read about finance (valuation) should stick with copeland et al, and who wants to read about ipos should try articles by jay ritter.
Rating: 2 out of 5
bad writing
I read the first 20 pages of this book and quit. It was too painful to keep going. The author's wording in convoluted, tangential, and just plain annoying. She throws out dozens of names from the industry, so many you can't keep them straight. There is poor flow to the writing, so you cannot understand why she is telling you things from one line to the next. The topics of each paragraph jump from one subject to another with abrupt, confusing transitions. I returned the book! Similar Products
The Biotech Investor: How to Profit from the Coming Boom in Biotechnology
The Biotech Investor's Bible
BILLION DOLLAR MOLECULE: THE QUEST FOR THE PERFECT DRUG
Book Index